logo-loader
viewAllergy Therapeutics PLC

Allergy Therapeutics grows market share ahead of key trial results

Interim revenues at the hay fever vaccine specialist rose by 4% to £42.2mln

Girl
Results from two trials are due this year

Allergy Therapeutics plc (LON:AGY) made further market share gains as it headed into a ‘pivotal’ twelve months.

Interim revenues at the hay fever vaccine specialist rose by 4% to £42.2mln despite the pollen season being described as ‘abnormally weak’.

WATCH: 'Pivotal' year ahead for Allergy Therapeutics with key trial readouts

Pollinex’s market share in Germany, its core market, rose one point to 14%, while bee and wasp sting product Venomil and Acarovac in Spain sold well.

Profits eased slightly to £6.03mln (£7.2mln) as Allergy increased R&D spending as two clinical trials moved into critical stages.

Headline or first glance data from the Phase III Pollinex Quattro Birch study in Europe is expected in the second half of the year along with first results from a Grass MATA MPL Phase II trial. 

That trial is especially important said Manuel Llobet, chief executive, as it “provides us the platform to expand into the lucrative US market”.

Spending on the trials will peak in the second half of the year, which will double the first half’s £5.9mln R&D costs.

Net sales of the existing products are again expected to run ahead of the market in the second half.

“Our continued focus on new product development is illustrated by our work on Polyvac Peanut,” added Llobet.

“Whilst at an early stage, we believe that our well-established, innovative approach to immunising patients from allergy symptoms could provide a new approach to combating this severe affliction.”

Cash at the end of the period was £25.8mln.

Quick facts: Allergy Therapeutics PLC

Price: 13.5501 GBX

AIM:AGY
Market: AIM
Market Cap: £86.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

2 min read